The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 April 2026•

1 min read

XORTX Therapeutics Completes Acquisition of Novel Kidney Disease Asset

Logos of Mineralys Therapeutics and Jefferies on an orange background with financial charts, chemical structures, microscopes, lab equipment, vials, and pills.

Key Facts

1XORTX announced the closing of the acquisition of the VB4-P5 asset, a novel anti-fibrotic chemical entity.

XORTX Therapeutics Inc. has officially finalized the acquisition of VB4-P5, a novel anti-fibrotic chemical entity, from Vectus Biosystems. This strategic move aims to expand the company's clinical portfolio and address significant unmet medical needs within the chronic kidney disease (CKD) market. The VB4-P5 asset is designed to target both rare kidney conditions and larger-scale CKD markets, offering a versatile therapeutic approach. By integrating this new asset, XORTX strengthens its intellectual property position and enhances its long-term growth potential in the biotechnology sector. Investors are viewing the acquisition as a positive step toward diversifying the company’s drug pipeline. The completion of this deal marks a key milestone in XORTX's mission to deliver innovative treatments for life-threatening renal diseases.